| Title |
Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, January 2021
|
| DOI | 10.1158/1535-7163.mct-20-0253 |
| Pubmed ID | |
| Authors |
Juan Manuel García-Martínez, Shirley Wang, Cordula Weishaeupl, Andreas Wernitznig, Paolo Chetta, Catarina Pinto, Jason Ho, Darrin Dutcher, Philip N Gorman, Rachel Kroe-Barrett, Joerg Rinnenthal, Craig Giragossian, Maria Antonietta Impagnatiello, Iñigo Tirapu, Frank Hilberg, Norbert Kraut, Mark Pearson, Klaus Peter Kuenkele |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 33% |
| Austria | 4 | 33% |
| Canada | 2 | 17% |
| Unknown | 2 | 17% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 6 | 50% |
| Members of the public | 4 | 33% |
| Science communicators (journalists, bloggers, editors) | 2 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 2 | 6% |
| Student > Master | 2 | 6% |
| Student > Ph. D. Student | 2 | 6% |
| Other | 1 | 3% |
| Lecturer | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 21 | 68% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 3 | 10% |
| Immunology and Microbiology | 3 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Medicine and Dentistry | 2 | 6% |
| Unknown | 21 | 68% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 January 2024.
All research outputs
#2,743,712
of 25,637,545 outputs
Outputs from Molecular Cancer Therapeutics
#339
of 4,083 outputs
Outputs of similar age
#73,906
of 526,515 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#10
of 58 outputs
Altmetric has tracked 25,637,545 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,083 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 526,515 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.